Braidwell’s Travere Therapeutics TVTX Stock Holding History

Braidwell’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,455,585	Closed	-$30.6M	–	97
2022 Q4	$30.6M	Buy	+1,455,585	New	+$30.8M	1.03%	39

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Braidwell's TVTX Position: Q1 2023 in Review

Braidwell sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 1,455,585 shares — an estimated $30.6M sold.

Braidwell first reported a position in TVTX in Q4 2022 and held it in 1 quarter. The position peaked at $30.6M in Q4 2022. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

Braidwell reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
Braidwell sold 1,455,585 Travere Therapeutics shares in Q1 2023, an estimated $30.6M.
Braidwell first reported a position in Travere Therapeutics in Q4 2022 and held it in 1 quarter.
Braidwell's Travere Therapeutics position peaked at $30.6M in Q4 2022.
174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.